Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Pharma & Drugs
Share your love
Lupin signs definitive agreement to acquire VISUfarma | Ophthalmology Times
(Image Credit: AdobeStock/Rido) Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its European business, as well as advance the…
Q&A: Nadia Waheed on the role of OCT in the future of ophthalmology | Ophthalmology Times
Photo of Nadia Waheed at the 2025 EURETINA meeting held in Paris, France Ultra High Resolution OCT is revolutionizing retinal imaging, offering unprecedented insights into eye diseases. Nadia Waheed, MD, MPH, from Tufts University School of Medicine discusses how this…
Positive pediatric data emerge from the OPGx-LCA5 phase 1/2 trial of Leber congenital amaurosis type 5 | Ophthalmology Times
Image credit: AdobeStock/arturkowynia Opus Genetics today announced the positive 3-month pediatric data from its Phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber congenital amaurosis type 5 (LCA5), an ultra-rare form…
Q&A: Patricio Schlottmann discusses results of AVONELLE-X faricimab extension trial | Ophthalmology Times
Photo of Patricio Schlottmann at the 2025 EURETINA meeting in Paris, France Patricio Schlottmann, MD, a retina specialist from Buenos Aires, Argentina, discusses the AVONELLE-X extension study of faricimab, a treatment for wet age-related macular degeneration (AMD). The study, spanning…
Kala Bio’s CHASE trial misses primary endpoint, KPI-012 development discontinued | Ophthalmology Times
(Image Credit: AdobeStock) Kala Bio announced that CHASE (NCT05727878), its phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect (PCED), did not meet its primary endpoint. Additionally, the company noted that the trial failed to show statistical significance…
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitors | Ophthalmology Times
Photo of Mark Gillies at the 2025 EURETINA meeting Mark Gillies, MD, PhD, introduced the Fight Retinal Blindness! Project, a comprehensive registry tracking VEGF inhibitor eye injection outcomes since 2007. Spanning 20 countries with 150 active practitioners, the project uniquely…
The Netherlands: Lupin strengthens ophthalmology business with acquisition of VISUfarma from GHO Capital
\n European specialist investor GHO Capital Partners has announced the sale of its portfolio company, VISUfarma, a Netherlands-headquartered specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin. \n\n\n\n VISUfarma was created by GHO Capital in 2016 by combining…
Q&A: Marion Munk discusses the phase 2a BETTER study | Ophthalmology Times
Photo of Marion Munk at EURETINA 2025 In her conversation with the Eye Care Network, Marion Munk, MD, PhD, details a promising phase 2a clinical study of ISTH0036, an oligonucleotide antisense drug targeting TGF-β2. Developed to address fibrosis in neovascular…
FDA approves abbreviated new drug application from Amneal Pharmaceuticals for bimatoprost ophthalmic solution 0.01% | Ophthalmology Times
(Image Credit: AdobeStock) The US Food and Drug Administration (FDA) has approved Amneal Pharmaceuticals’ Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL).1 An ANDA is a submission to the FDA that…
Luxa Biotechnology announces clinical trial results for treatment of AMD | Ophthalmology Times
(Image credit: ©Alex_Traksel/AdobeStock) Luxa Biotechnology LLC announced results from its phase 1/2a clinical trial titled “Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation in Patients with Dry Age-related Macular Degeneration: Low Dose Clinical Outcomes.”1 The results were published…